NAFLD vs MASLD & NASH vs MASH: The 2026 Guide to What Changed
In the world of hepatology and metabolic health, we are witnessing a massive paradigm shift. What we historically referred to as NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis) have officially entered a new era of nomenclature and clinical management.
This isn't just a minor tweak in vocabulary. The transition from NAFLD to MASLD and NASH to MASH represents a fundamental evolution in how we view, diagnose, and treat liver disease.
The 2023 Breakthrough: Why the Name Changed
In June 2023, an international consensus led by major global liver societies (including AASLD, EASL, and ALEH) announced a landmark nomenclature change. For decades, the terms "fatty" and "non-alcoholic" had faced growing criticism. This historic change aimed to solve two major clinical issues:
- Reducing Patient Stigma: The word "fatty" can carry unintended social stigma, making patient communication unnecessarily difficult.
- Moving Past Exclusionary Definitions: Defining a disease by what it is not ("non-alcoholic") is poor medicine. It failed to identify the actual root cause of the condition and excluded patients who had both metabolic syndrome and a history of moderate alcohol consumption.
"By shifting the focus directly to metabolic health, clinicians can explain the condition as a metabolic disease rather than a diagnosis defined solely by the absence of alcohol intake."
Mapping the Nomenclature Change
To help navigate this transition, here is a breakdown of the old terminology versus the new, positive-definition counterparts:
| Old Terminology (Pre-2023) | New Terminology (2023–Present) | Key Clinical Distinction |
|---|---|---|
| NAFLD Nonalcoholic Fatty Liver Disease |
MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease |
Requires the presence of hepatic steatosis (liver fat accumulation) plus at least one of five cardiometabolic risk factors. |
| NASH Nonalcoholic Steatohepatitis |
MASH Metabolic Dysfunction-Associated Steatohepatitis |
The active, progressive form of MASLD characterized by liver cell inflammation and injury, which can lead to advanced fibrosis. |
| NAFL Nonalcoholic Fatty Liver |
MASL Metabolic Dysfunction-Associated Steatotic Liver |
Simple liver fat accumulation without significant active inflammation. |
| No equivalent category | MetALD | A vital new category for patients who have MASLD but also consume higher amounts of alcohol, allowing for personalized, dual-etiology care. |
The Diagnostic Criteria for MASLD
To receive a diagnosis of MASLD today, a patient must have imaging or histological evidence of liver fat (steatosis) paired with at least one of the following cardiometabolic criteria:
- Overweight/Obesity: BMI ≥ 25 kg/m² (or ≥ 23 kg/m² for Asian populations) or a high waist circumference.
- Impaired Glucose Regulation: Type 2 diabetes, prediabetes, or insulin resistance.
- Hypertension: Blood pressure ≥ 130/85 mmHg or active antihypertensive therapy.
- High Triglycerides: Plasma triglycerides ≥ 150 mg/dL or active lipid-lowering therapy.
- Low HDL Cholesterol: HDL ≤ 40 mg/dL for men and ≤ 50 mg/dL for women.
The 2026 Reality: Clinical Guidelines & Therapeutics
Fast forward to 2026: the global medical community has fully integrated this terminology, and the clinical landscape has evolved rapidly. What was once primarily a monitoring and lifestyle-modification disease has now become a highly active therapeutic frontier.
1. Screening with Non-Invasive Tests (NITs)
In routine practice, clinical guidelines strongly recommend risk-stratifying MASLD patients using non-invasive tools rather than relying immediately on invasive liver biopsies. The FIB-4 (Fibrosis-4) index is now the standard, widely accessible first-line screening tool. If FIB-4 scores indicate intermediate or high risk, clinicians escalate to secondary assessments using Vibration-Controlled Transient Elastography (VCTE / FibroScan) to measure liver stiffness before referring patients to specialists.
2. Approved Medical Treatments are Finally Here
For years, physicians had no targeted FDA-approved options for progressive MASH. Today, that has completely changed:
- THR-β Agonists: Resmetirom (Rezdiffra), which acts as a thyroid hormone receptor-beta agonist in the liver, remains a cornerstone treatment after securing historical approvals for adults with non-cirrhotic MASH and moderate-to-advanced (F2-F3) liver fibrosis.
- Incretin Mimetics (GLP-1s and dual-agonists): Medications like Semaglutide and dual-agonists like Survodutide have showcased stellar Phase 3 results, successfully achieving MASH resolution and offering crucial cardiometabolic protection.
3. The Rise of "Lean MASLD"
2026 clinical guidelines have thrown a spotlight on Lean MASLD—a highly underrecognized phenotype where patients of normal body mass index (BMI) still accumulate pathologic liver fat due to visceral adiposity, genetic variants, and underlying insulin resistance. Studies show these individuals often carry high cardiometabolic risks and require proactive cardiovascular screening.
Takeaway for Patients and Providers
The journey from NAFLD to MASLD has proved to be much more than a cosmetic rebrand. It has restructured how clinics approach liver health, allowing for earlier screening, non-stigmatizing patient education, and highly targeted metabolic interventions. Whether you are a provider tracking the newest guidelines or a patient keeping tabs on your liver health, metabolic-focused care is the definitive path forward.
Comments